Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

Journal of Clinical Oncology

Volumn 21, Issue 10, 2003, Pages 1980-1987

  Cohen, Ezra E W ^a   Rosen, Fred ^a   Stadler, Walter M ^a   Recant, Wendy ^a   Stenson, Kerstin ^a   Huo, Dezheng ^a   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 3; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG INHIBITION; DRUG RESPONSE; DRUG TOLERABILITY; FEEDING APPARATUS; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PATIENT ASSESSMENT; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SINGLE DRUG DOSE; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; DIGESTIVE TRACT INTUBATION; DISEASE FREE SURVIVAL; DRUG EFFECT; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; ILLINOIS; IMMUNOHISTOCHEMISTRY; INTUBATION, GASTROINTESTINAL; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037674062     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.051     Document Type: Article

References (33)

1. Liverpool Head and Neck Oncology Group: A phase III randomised trial of cisplatinum, methotrexate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 61:311-315, 1990
2. Clavel M, Vermorken JB, Cognetti F, et al: Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5:521-526, 1994
3. Forastiere AA, Metch B, Schuller DE, et ai: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 10:1245-1251, 1992
4. Forastiere AA, Leong T, Rowinsky E, et al: Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 19:1088-1095, 2001
5. Jacobs C, Lyman G, Velez-Garcia E, et al: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257-263, 1992
6. Schrijvers D, Johnson J, Jiminez U, et al: Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer: Head and Neck Interferon Cooperative Study Group. J Clin Oncol 16:1054-1059, 1998
7. Cohen S, Carpenter G, King L Jr: Epidermal growth factor-receptor-protein kinase interactions: Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 255:4834-4842, 1980
8. Olayioye MA, Neve RM, Lane HA, et al: The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19:3159-3167, 2000
9. Kolch W: Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351:289-305, 2000
10. Baselga J, Averbuch SD: ZD1839 ('Iressa') as an anticancer agent. Drugs 60:33-40, 2000 (suppl)
11. Zwick E, Bange J, Ullrich A: Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8:17-23, 2002
12. Busse D, Doughty RS, Ramsey TT, et al: Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem 275:6987-6995, 2000
13. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958-2970, 2001
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
15. Shin DM, Glisson BS, Khuri FR, et al: Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 16:1325-1330, 1998
16. Shin DM, Khuri FR, Glisson BS, et al: Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 91:1316-1323, 2001
17. Murphy B, Li Y, Cella D, et al: Phase III study comparing cisplatin (C) and 5-flurouracil (F) versus cisplatin and paclitaxel (T) in metastatic/recurrent head and neck cancer (MHNC). Proc Am Soc Clin Oncol 20:224a, 2001 (abstr 894)
18. Kies M, Arquette M, Nabell L, et al: Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225) in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 21:232A, 2002 (abstr 925)
19. Baselga J, Trigo J, Bourhis J, et al: Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol 21:226a, 2002 (abstr 900)
20. Burtness B, Li Y, Flood W, et al: Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC). Proc Am Soc Clin Oncol 21:226a, 2002 (abstr 901)
21. Senzer N, Soulieres D, Siu L, et al: Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 20:2a, 2001 (abstr 6)
22. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
23. Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20:2240-2250, 2002
24. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914, 2000
25. Shin DM, Donato NJ, Perez-Soler R, et al: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7:1204-1213, 2001
26. Ratain M, George C, Janisch L, et al: Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 21:75b, 2002 (abstr 2115)
27. Herbst RS, Maddox AM, Rothenberg ML, et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a Phase I trial. J Clin Oncol 20:3815-3825, 2002
28. Goss G, Hirte H, Lorimer I, et al: Final results of the dose escalation phase of a phase I pharmacokinetics (PK), pharmacodynamic (PD) and biological activity study of ZD1839: NCIC CTG Ind 122. Proc Am Soc Clin Oncol 20:85, 2001 (abstr 335)
29. Saltz L, Rubin MS, Hochster HS, et al: Acne-like rash predicts response in patients treated with Cetuximab (IMC-C225) plus Irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). American Association for Cancer Research/National Cancer Institute/European Organization for Research and Treatment of Cancer International Conference, Miami, FL, 2001 (abstr)
30. Fukuoka M, Yano S, Giaccone G, et al: Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 21:298a, 2002 (abstr 1188)
31. Kris M, Natale R, Herbst R, et al: A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21:292a, 2002 (abstr 1166)
32. Albanell J, Codony-Servat J, Rojo F, et al: Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61:6500-6510, 2001
33. Hidalgo M, Malik S, Rowinsky E, et al: Inhibition of the epidermal growth factor receptor (EGFR) by OSI-774, a specific EGFR inhibitor in malignant and normal tissues of cancer patients. Proc Am Soc Clin Oncol 21:71a, 2002 (abstr 281)